12:00 AM
 | 
Mar 06, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Novantrone mitoxantrone chemotherapeutic inhibitor of DNA replication regulatory update

IMNX received an approvable letter from the FDA for Novantrone to slow progression of neurologic disability and reduce...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >